新城發展(01030.HK)上半年合同銷售額1,176.6億人幣 按年增20.7%
新城發展(01030.HK)公佈,於今年6月,集團實現合約銷售金額約230.25億元人民幣(下同),按年下跌11.7%;合約銷售面積約183.16萬平方米。
今年上半年,集團累計合同銷售金額約1,176.64億元,按年增20.7%;累計銷售面積約1,086.96萬平方米。而今年上半年吾悅廣場累計租金收入約36.67億元。
另外,集團子公司通過掛牌方式取得湖北省武漢市地塊。該項目位於武漢市蔡甸區蔡甸街新天大道與知音湖大道交匯處以南,出讓面積爲10.89萬平方米,規劃用途爲居住、商服用地,計容建築面積約24.4萬平方米。集團共需支付土地價款7.14億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.